Royalty Pharma (RPRX) Q3 2024 earnings summary

Executive summary

• Achieved 15% year-over-year growth in Portfolio and Royalty Receipts for Q3 2024, reaching $735 million and $732 million, respectively, reflecting strong execution and recurring cash inflows.

• Net income attributable to Royalty Pharma plc surged to $544 million in Q3 2024, up from $72 million in Q3 2023.

• Deployed $1.2 billion in capital during Q3 and $2.6 billion year-to-date, including acquisitions of royalties on Niktimvo, Yorvipath, and deucrictibant, and repurchased $95 million in shares in Q3.

• FDA approvals for Cobenfy, Tremfya, and Voranigo in new indications enhanced the portfolio and contributed to raised full-year 2024 guidance.

• Maintained leadership in the biopharma royalty market with interests in over 35 commercial products and 15 development-stage candidates.

Financial highlights

• Q3 2024 Royalty Receipts and Portfolio Receipts both grew 15% year-over-year, reaching $735 million and $732 million, respectively.

• Adjusted EBITDA margin for Q3 2024 was approximately 92% of Portfolio Receipts; Portfolio Cash Flow margin was about 84%.

• Net income for Q3 2024 was $544 million, with basic EPS of $1.22, up from $0.16 in Q3 2023.

• Cash and cash equivalents at quarter-end were $950 million; total debt outstanding was $7.8 billion.

• Repurchased 3 million shares for $95 million in Q3 and 7 million shares for $180 million year-to-date; $484 million spent under the $1 billion buyback program since March 2023.

Outlook and guidance

• Full-year 2024 Portfolio Receipts guidance raised to $2.75–$2.8 billion, with Royalty Receipts growth forecasted at 11%-13% year-over-year.

• Milestones and other contractual receipts expected to decline from $600 million in 2023 to $30 million in 2024 due to a high base from prior accelerated payments.

• Operating and professional costs projected at 8.5% of Portfolio Receipts; interest paid for 2024 expected at $160 million.

• Guidance assumes no major adverse events or significant FX changes.